India's Epigral climbs to six-week high after Systematix starts coverage at 'buy'
BUZZ-India's Epigral climbs to six-week high after Systematix starts coverage at 'buy' ** Shares of chemicals maker Epigral EPIG.NS rise as much as 8.5% to a six-week high of 1,175.50 rupees after Systematix starts coverage with a "buy" rating
** Brokerage sets a target price of 1,380 rupees, implying a 27.4% upside from the stock's last close
** Systematix says EPIG is well-placed to benefit from strong Indian demand for newer products such as epichlorohydrin, chlorinated polyvinyl chloride and chloretoluene
** Also points to the company's integrated operations, energy-saving measures and raw material strategy as competitive strengths
** Systematix expects revenue to grow at a 19% annual pace over FY2026-FY2028
** Says valuations remain attractive at current levels of 11x FY2028 P/E compared to 20.5x 5-year historical average
** EPIG shares down 7.5% in 2026 so far, according to exchange data
(Reporting by Bharath Rajeswaran in Bengaluru)
((bharath.rajeswaran@thomsonreuters.com; +91 9769003463;))
Recent news on Epigral
See all newsBrief: Epigral Ltd Proposes To Establish New Manufacturing Facility For Epoxy Resin & Formulations At Existing Facility At Dahej
Brief: Epigral June-Quarter Consol Net Profit 997.4 Million Rupees
India's Epigral climbs to six-week high after Systematix starts coverage at 'buy'
Brief: Epigral Ltd Dec-Quarter Consol Net Profit 391.1 Million Rupees
Brief: Epigral Gets Tax Demand For 525.2 Million Rupees